Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
D. Western Therapeutics Institute. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
D. Western Therapeutics Institute's
is considered below, and whether this is a fair price.
Price based on past earnings
D. Western Therapeutics Institute's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as D. Western Therapeutics Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
D. Western Therapeutics Institute
expected to grow at an
Unable to compare D. Western Therapeutics Institute's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare D. Western Therapeutics Institute's earnings growth to the Germany market average as no estimate data is available.
Unable to compare D. Western Therapeutics Institute's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if D. Western Therapeutics Institute is high growth as no earnings estimate data is available.
Unable to determine if D. Western Therapeutics Institute is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
D. Western Therapeutics Institute's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
D. Western Therapeutics Institute
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
D. Western Therapeutics Institute's finances.
The net worth of a company is the difference between its assets and liabilities.
D. Western Therapeutics Institute is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
D. Western Therapeutics Institute's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
D. Western Therapeutics Institute's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 2.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Hiroyoshi Hidaka, M.D., Ph.D. founded D.Western Therapeutics Institute in 1999 and has been its Chairman since June 2012 and also has been chief Science Officer Since June, 2010 and serves as its Chief Executive Officer. Dr. Hidaka serves as a Manager of Research and Development Center, Director of DWTI since December 2004. Mr. Hidaka has been Guest Professor at Duke University, U.S. since July 1998. He served as Chief Technology Officer of D.Western Therapeutics Institute and served as its Chief Science Officer since June 2010. He served as an Associate Professor, Faculty of Medicine at Kyoto University since April 1976, as Professor, Faculty of Medicine at Mie University since January 1978 and as Professor, Faculty of Medicine at Nagoya University since August 1987. Mr. Hidaka was a Professor at Nagoya University School of Medicine and an Adjunctive Professor at Duke University Medical Center. He has been an Executive Director of D.Western Therapeutics Institute since December 2004. He holds an M.D. and Ph.D. from Nagoya University School of Medicine.
Insufficient data for Hiroyoshi to compare compensation growth.
Insufficient data for Hiroyoshi to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
GM of Administration Division & Director
Board of Directors Tenure
Average tenure and age of the
D. Western Therapeutics Institute
board of directors in years:
The tenure for the D. Western Therapeutics Institute board of directors is about average.
D. Western Therapeutics Institute, Inc., a biotechnology company, develops drugs to serve patients worldwide. The company offers GLANATEC, an ophthalmic solution for the treatment of glaucoma/ocular hypertension. It is also developing K-134, an anti-platelet that has completed phase IIb trial for the treatment of arteriosclerosis obliterans; WP-1303(H-1129), which has completed phase II trial for the treatment of glaucoma/ocular hypertension; H-1337, a multikinase inhibitor, which has completed phase I/IIA clinical trials for the treatment of glaucoma and ocular hypertension; and DW-1002, an ophthalmic surgical adjuvant for the cataract surgeries, and ILM staining and peeling. In addition, the company is developing ophthalmic analgesic. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.